Investigational drug · Phase 3
NP-101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Gastroenteropancreatic Neuroendocrine Tumors.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
12
Any phase or sponsor naming "NP-101"
First trial start
2027
Jan 2027
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NP-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Gastroenteropancreatic Neuroendocrine Tumors
Approved drugs for the same conditions: Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "NP-101" as an intervention, largest first.
- The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute MigrainePivotal-lookingCompleted
NuPathe Inc.Industry
NCT00724815 · 530 participants · Start Jan 2009 · Primary completion Jul 2009
Drug: NP101 - Sumatriptan iontophoretic transdermal patch; Placebo · For: Migraine Disorders
Sites: Phoenix, Arizona; Little Rock, Arkansas; Newport Beach, California · 34 sites in all
- An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve MonthsPivotal-lookingCompleted
NuPathe Inc.Industry
NCT00806546 · 514 participants · Start Feb 2009 · Primary completion May 2011
Drug: NP101 · For: Migraine Disorders
Sites: Phoenix, Arizona; Scottsdale, Arizona; Irvine, California · 31 sites in all
- A Multicenter Study Evaluating the Efficacy and Safety of Nivolumab and Ipilimumab in Combination With NP-101 Versus Placebo in Refractory Advanced and Metastatic Gastroenteropancreatic Neuroendocrine Carcinomas (GEP-NECs)Pivotal-lookingNot yet recruiting
Novatek PharmaceuticalsIndustry
NCT07935928 · 381 participants (planned) · Start Jan 2027 · Primary completion Dec 2029
Drug: NP-101; Ipi/Nivo · For: Gastroenteropancreatic Neuroendocrine Tumors
- An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 MonthsPivotal-lookingCompleted
NuPathe Inc.Industry
NCT00792103 · 198 participants · Start Jan 2009 · Primary completion Sep 2010
Drug: NP101 · For: Migraine Disorders
Sites: Phoenix, Arizona; Little Rock, Arkansas; Newport Beach, California · 34 sites in all
- Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive.Pivotal-lookingTerminated
Novatek PharmaceuticalsIndustry
NCT05785390 · 170 participants · Start Feb 22, 2023 · Primary completion May 9, 2025
Drug: NP-101 · For: COVID-19
Sites: Miami, Florida; Berwyn, Illinois; Houston, Texas · 4 sites in all
NuPathe Inc.Industry
NCT01381796 · 63 participants · Start Dec 2009 · Primary completion Sep 2010
Drug: NP101; sumatriptan succinate · For: Compare Bioequivalence Patches Previously Used in the NP101-007 Study
Sites: Saint Paul, Minnesota
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT06563375 · 35 participants (planned) · Start Mar 5, 2025 · Primary completion Sep 1, 2028
Drug: NP-101 · For: Solid Tumor
Sites: Houston, Texas
NuPathe Inc.Industry
NCT00546650 · 25 participants · Start Nov 2007 · Primary completion Dec 2007
Drug: Sumatriptan succinate; Sumatriptan succinate · For: Healthy
Sites: Orlando, Florida
NuPathe Inc.Industry
NCT00723983 · 23 participants · Start Nov 2008 · Primary completion Sep 2009
Drug: Sumatriptan succinate; NP101 Study Patch · For: Migraine Disorders
Sites: Hallandale, Florida
Amr Mohamed MDAcademic, hospital or other
NCT05262556 · 15 participants · Start Dec 15, 2022 · Primary completion Oct 27, 2025
Drug: NP-101 (TQ Formula); Nivolumab (3mg/kg) and 1 more · For: Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Neoplasm; Neuroendocrine Carcinoma and 1 more
Sites: Cleveland, Ohio
Newest research
PubMed records naming it or its code names, newest first.
- NP-101 in combination with nivolumab and ipilimumab in metastatic extrapulmonary neuroendocrine carcinomas (EP-NECs): A pilot study.
Mohamed A, Azmi A, Kocak M, et al. · Endocr Relat Cancer 2026
- Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection.
Maen A, Gok Yavuz B, Mohamed YI, et al. · Front Pharmacol 2024
- Autism spectrum disorder in architecture perspective: a review of the literature and bibliometric assessment of research indexed in Web of Science.
Moniem Ali R, El-Wakeel HA, Al-Saleh DF, et al. · F1000Res 2021
- Heme oxygenase-1 is a potent inhibitor of placental ischemia-mediated endothelin-1 production in cultured human glomerular endothelial cells.
Bakrania BA, Spradley FT, Satchell SC, et al. · Am J Physiol Regul Integr Comp Physiol 2018
- Vitamin D supplementation reduces some AT1-AA-induced downstream targets implicated in preeclampsia including hypertension.
Faulkner JL, Amaral LM, Cornelius DC, et al. · Am J Physiol Regul Integr Comp Physiol 2017
- Dislocation-induced nanoparticle decoration on a GaN nanowire.
Yang B, Yuan F, Liu Q, et al. · ACS Appl Mater Interfaces 2015
Also in development for Gastroenteropancreatic Neuroendocrine Tumors
- Lutetium[177Lu] Oxodotreotidedotatate, 177Lu-DOTA0-Tyr3-OctreotatePhase 33 trials
Sinotau Pharmaceutical Group · Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.